Tack CJ, et al. - Among patients with type 2 diabetes enrolled in the LEADER trial, researchers evaluated liraglutide for its long-term effectiveness in subgroups by insulin use. At baseline, 5,171 (55%), 3,159 (34%), and 1,010 (11%) patients were reported as not receiving insulin, receiving basal-only insulin, and receiving other insulins, respectively. Improved glycemic control, weight, and requirement for insulin were reported for at least 36 months in patients on insulin in response to treatment with liraglutide vs placebo, with no increased risk of severe hypoglycemia. Cardiovascular safety/efficacy was also maintained. Based on these findings, the combination of liraglutide and insulin for type 2 diabetes management is supported.